As previously reported, Ladenburg upgraded Zynex (ZYXI) to Buy from Neutral with a $3.70 price target While the firm recognizes disruptions in the pain segment are “material,” creating uncertainty and negatively impacting the company’s performance, it argues that the opportunity for the NiCO laser pulse oximeter “should not be overlooked,” citing the differentiated technology and agency-driven efforts to provide more equitable care.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYXI: